Minerva Neurosciences, Inc. Deferred State and Local Income Tax Expense (Benefit)
Minerva Neurosciences, Inc. (NERV) reported Deferred State and Local Income Tax Expense (Benefit) of -$1.16 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-08.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2023-03-08
- Minerva Neurosciences, Inc. deferred state and local income tax expense (benefit) for fiscal 2021 was -$1.16M.
- Minerva Neurosciences, Inc. deferred state and local income tax expense (benefit) for fiscal 2019 was -$134.42K.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month |
|---|---|
| 2021-12-31 | -$1.16M 10-K · filed 2023-03-08 |
| 2019-12-31 | -$134.42K 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |